ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

31.05

+0.05 (0.16%)

Apr 24, 2026, 12:23 PM EDT - Market open

ArriVent BioPharma Earnings Call Transcripts

Fiscal Year 2025

Study Update

FV102 demonstrated significant protection against gluten-induced gut inflammation and symptoms in celiac disease, with a strong safety profile and plans for a larger phase 2 trial using composite histological and symptom endpoints.

Read full transcript →

Press Release Slides

Powered by